Animal Drug User Fee Rates and Payment Procedures for Fiscal Year 2027
Published Date: 7/30/2026
Notice
Summary
The Food and Drug Administration (FDA, the Agency, or we) is announcing the fee rates and payment procedures for fiscal year (FY) 2027 animal drug user fees. The Federal Food, Drug, and Cosmetic Act (FD&C Act), as amended by the Animal Drug User Fee Amendments of 2023 (ADUFA V), authorizes FDA to collect user fees for certain animal drug applications and supplemental animal drug applications, for certain animal drug products, for certain establishments where such products are made, and for certain sponsors of such animal drug applications and/or investigational animal drug submissions. This notice establishes the fee rates for FY 2027.
Analyzed Economic Effects
5 provisions identified: 2 benefits, 3 costs, 0 mixed.
FY2027 Animal Drug Fee Levels
If you submit or sponsor animal drug applications, FY2027 fees are set at these rates: animal drug application $621,692; supplemental application $310,846; product fee $12,294; establishment fee $215,520; sponsor fee $145,476. These fee rates apply to applications submitted on or after October 1, 2026 and remain in effect through September 30, 2027.
Invoice Timing and Payment Deadlines
FDA will issue invoices for FY2027 product, establishment, and sponsor fees by December 31, 2026, and payment for those invoices is due by January 31, 2027. Application fees are effective for submissions on or after October 1, 2026; payments can be made online via Pay.gov or by wire transfer using the Treasury account info provided.
Full Payment Required Before Review
FDA will not accept an animal drug application for review until it has received full payment of the application fee and any other ADUFA fees owed. That requirement applies to applications submitted on or after October 1, 2026.
Barrier-to-Innovation Waiver Rules
FDA may waive or reduce ADUFA fees under a 'Barrier to Innovation' test if an applicant both (1) is pursuing an innovative product/technology and (2) would face a significant barrier because of limited resources. For FY2027, FDA uses an inflation-adjusted financial resource ceiling of $25,493,000 to identify limited resources. Waiver requests must be submitted in writing no later than 180 days from when fees are due and a granted waiver is valid for one fiscal year.
Operating Reserve Reduced FY2027 Fees
FDA applied an operating reserve adjustment of $5,834,940 because projected carryover user fees exceeded the 18-week threshold; this decreased the FY2027 target fee revenue to $32,328,000. That lowered target revenue was used to set the FY2027 fee amounts listed in the fee schedule.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2026-15345, Food Safety Modernization Act Voluntary Qualified Importer Program User Fee Rate for Fiscal Year 2027
The Food and Drug Administration (FDA or we) is announcing the fiscal year (FY) 2027 annual fee rate for importers approved to participate in the Voluntary Qualified Importer Program (VQIP) that is authorized by the Federal Food, Drug, and Cosmetic Act (FD&C Act), as amended by the FDA Food Safety Modernization Act (FSMA). This fee is effective on August 1, 2026, and will remain in effect through September 30, 2027.
2026-15336, Food Safety Modernization Act Domestic and Foreign Facility Reinspection, Recall, and Importer Reinspection Fee Rates for Fiscal Year 2027
The Food and Drug Administration (FDA or we) is announcing the fiscal year (FY) 2027 fee rates for certain domestic and foreign facility reinspections, failures to comply with a recall order, and importer reinspections that are authorized by the Federal Food, Drug, and Cosmetic Act (FD&C Act), as amended by the FDA Food Safety Modernization Act (FSMA).
2026-15346, Biosimilar User Fee Rates for Fiscal Year 2027
Starting October 1, 2026, companies making biosimilar drugs will pay updated fees to the FDA for developing and getting approval for their products. These fees cover new drug development, application reviews, and yearly program costs. This helps the FDA keep biosimilar drug reviews speedy and fair while supporting innovation.
2026-15335, Medical Device User Fee Rates for Fiscal Year 2027
The Food and Drug Administration (FDA, Agency, or we) is announcing the fee rates and payment procedures for medical device user fees for fiscal year (FY) 2027. The Federal Food, Drug, and Cosmetic Act (FD&C Act), as amended by the Medical Device User Fee Amendments of 2022 (MDUFA V), authorizes FDA to collect user fees for certain medical device submissions and annual fees both for certain periodic reports and for establishments subject to registration. This notice establishes the fee rates for FY 2027, which apply from October 1, 2026, through September 30, 2027, and provides information on how the fees for FY 2027 were determined, the payment procedures you should follow, and how you may qualify for reduced small business fees.
Previous / Next Documents
Previous: 2026-15338, Crow Butte Resources, Inc.; Crow Butte Project and Marsland Expansion Area; Environmental Assessment and Finding of No Significant Impact
The U.S. Nuclear Regulatory Commission (NRC) is considering renewal of Crow Butte Resources, Inc.'s (CBR or the licensee), source and byproduct materials license SUA-1534 for continued in situ recovery (ISR) of uranium at the Crow Butte Project and for construction and operation of a satellite facility and support operations at the Marsland Expansion Area in Crawford, Nebraska, for an additional 20 years. The NRC staff is issuing an environmental assessment (EA) and finding of no significant impact (FONSI).
Next: 2026-15341, Animal Generic Drug User Fee Program Rates and Payment Procedures for Fiscal Year 2027
The Food and Drug Administration (FDA, the Agency, or we) is announcing the fee rates and payment procedures for fiscal year (FY) 2027 generic new animal drug program user fees. The Federal Food, Drug, and Cosmetic Act (FD&C Act), as amended by the Animal Generic Drug User Fee Amendments of 2023 (AGDUFA IV), authorizes FDA to collect user fees for certain abbreviated applications for generic new animal drugs, for certain generic new animal drug products, for certain sponsors of such abbreviated applications for generic new animal drugs and/or investigational submissions for generic new animal drugs (JINADs), and for certain submissions related to JINAD files. This notice establishes the fee rates for FY 2027.